Volume | 51 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioSig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.555 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
7 | 51 | - | 0.2619 - 16.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:44:52 | 3 | $ 1.71 | USD |
BioSig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
14.47M | 9.33M | - | 286k | -27.27M | -2.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioSig Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.06 | 2.44 | 1.06 | 1.57 | 1,620,247 | 0.495 | 46.70% |
1 Month | 0.54 | 2.98 | 0.4555 | 1.63 | 2,851,594 | 1.02 | 187.96% |
3 Months | 2.192 | 2.98 | 0.2619 | 1.36 | 1,325,141 | -0.637 | -29.06% |
6 Months | 5.66 | 5.80 | 0.2619 | 1.88 | 797,261 | -4.11 | -72.53% |
1 Year | 13.30 | 16.50 | 0.2619 | 5.57 | 652,412 | -11.75 | -88.31% |
3 Years | 38.40 | 45.80 | 0.2619 | 10.94 | 416,261 | -36.85 | -95.95% |
5 Years | 63.70 | 124.30 | 0.2619 | 33.72 | 414,632 | -62.15 | -97.56% |
BioSig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |